Condition (MeSH)
Mydriasis
ClinicalTrials.gov lists 37 trials for Mydriasis or a narrower condition beneath it. Eyenovia Inc. has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
37 of the 37 trials are tagged with Mydriasis itself; the rest are tagged with a narrower condition beneath it.
When did Mydriasis trials start? (16)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 7
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 4 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 7 |
| 2020 | 3 |
| 2019 | 3 |
| 2018 | 3 |
| 2016 | 2 |
| 2013 | 2 |
Showing 10 of 16 earlier years.
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Mydriasis trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 2 |
| Phase 2/3 | 2 |
| Phase 3 | 8 |
| Phase 4 | 9 |
| Not applicable | 12 |
| Observational | 2 |
How many Mydriasis trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Completed | 27 |
| Terminated | 2 |
| Unknown status | 6 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Mydriasis trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Eyenovia Inc. | 5 |
| Ocuphire Pharma, Inc. | 4 |
| Basque Health Service | 1 |
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Phentolamine Ophthalmic Solution Vehicle | 4 |
| Phentolamine Ophthalmic Solution 0.75% | 3 |
| tropicamide-phenylephrine fixed combination ophthalmic solution | 1 |
| Phenylephrine 10% Eyedrop | 1 |
| Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE) | 1 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Mydriasis? (13)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Study on the correlation between iris blood flow, iris thickness and pupil diameter in the resting state and after pharmacological mydriasis in patients with diabetes mellitus. | BMC ophthalmology | 2024 | Yes |
| Alternative mydriasis techniques for retinopathy of prematurity screening. | International ophthalmology | 2020 | Yes |
| Evaluation of the efficacy and safety of a standardised intracameral combination of mydriatics and anaesthetics for cataract surgery. | The British journal of ophthalmology | 2016 | Yes |
| 2.5% and 10% phenylephrine for mydriasis in diabetic patients with darkly pigmented irides. | Journal of the Medical Association of Thailand = Chotmaihet thangphaet | 2010 | Yes |
| Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma. | Cancer immunology, immunotherapy : CII | 2002 | Yes |
Showing 5 of 13 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.